EGFR and non-small cell lung carcinoma: In non‐small‐cell lung cancer (NSCLC), activation of the AXL receptor tyrosine kinase in the course of EMT provides resistance to EGFR and PI3K inhibition, dependent on sustained KRAS activity (Singh et al, 2009; Sequist et al, 2011; Zhang et al, 2012; Byers et al, 2013; Tulchinsky et al, 2019).